Advertisement


Ursula A. Matulonis, MD, and Nicoletta Colombo, MD, on Ovarian Cancer: Overall Survival Data on Relacorilant Plus Nab-Paclitaxel

2022 ASCO Annual Meeting

Advertisement

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, compared with nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer. A phase III trial comparing intermittent relacorilant plus nab-paclitaxel with investigator’s choice of chemotherapy in primary platinum-refractory disease is ongoing (Abstract LBA5503).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Ursula Matulonis: Nicoletta great to see you. Congratulations on this study. It's a really fascinating study with really intriguing results. Can you tell us about the mechanism of action of Relacorilant and how it inhibits ovarian cancer growth? Nicoletta Colombo: It has been shown that cortisol main use chemotherapy resistance by interfering with some apoptotic pathways, which cytotoxic agents such as Nab-Paclitaxel utilize. So basically Relacorilant is a selective glucocorticoid receptor modulator, and binds to the GI, the glucocorticoid receptor and suppresses the activity of cortisol. So in this way, of course, cytotoxic agents, such as Nab-Paclitaxel may use their apoptotic pathways and induce apoptosis and cells deaths. So that's the rational for using this drug in ovarian cancer patients. Ursula Matulonis: Yeah. It's a really unique, unique mechanism of action that I don't think's really been tested before. Nicoletta Colombo: No, it's really unique. It's very interesting because even very low level of cortisol may really induce chemotherapy resistance. So by suppressing this activity of cortisol, we may enhance the efficacy of cytotoxic agents. Ursula Matulonis: And in this trial, so there were three arms. There was control Nab-Paclitaxel and then two different schedules of Relacorilant added to Nab-Paclitaxel. Can you just, did you talk about those two different schedules and why they were tested? Nicoletta Colombo: Yeah. One schedule was just very, I mean, low level of continuous Relacorilant and the other one was Relacorilant given the day before, the day off, and the day after chemotherapy. Why that? Because on one end, continuous administration may provide a continuous antagonist of cortisol, but on the other hand, by giving higher dose of Relacorilant around times of maximum chemotherapy exposures may provide a better antagonist. So that's why we decided to use or to test these two different schedules. Ursula Matulonis: Yeah. Gotcha. And tell us about the results which are intriguing and I think really promising. Nicoletta Colombo: Yeah, this is a randomized phase two, and we enroll 178 patients in these three arms. So the comparator arm, which was Nab-Paclitaxel alone given the day 1, 8, 15 of a 28 day cycle. And then we have the two Relacorilant arm, the intermittent and continuous. These patients were really very heavily retreated patients up to five prior lines of chemotherapy. All but one had received prior taxane. More than 50% had received bevacizumab. And about one third had received even PARP inhibitors, so really a very, very heavily pretreated population. Moreover, 36% had a platinum refractory disease, and some of them even primary platinum refractory disease. And actually there was an unbalance on the percentage of patients with primary platinum refractory disease, which was higher in the intermittent scheduling arm. So, so patients were randomized in these three arms, and then the primary endpoint was progression free survival. And we presented already the data at ESMO last year, and we demonstrated a significant improvement in progression free survival for patients receiving the intermittent schedule of Relacorilant. And so this was the primary endpoint, but today, I mean at this conference, I will present the overall survival data. And it's very interesting because already at that time, we saw a trend for an improvement in overall survival. And this trend has been now confirmed. Actually, we see that for the intermittent schedule compared to the standard arm, we have a hazard ratio 0.67, which does not reach really statistically significant, but is very close. But what we did the scenes, as I said, there was an imbalance in the primary platinum refractory patients population, we perform subgroup analysis taking away the primary platinum refractory. And in this situation, the hazard ratio is 0.63 and becomes statistically significant. So I think this is a great news because we know that patients with platinum resistant ovarian cancer represent a very high unmet need. And we now have a completely different drug with a very unique mechanism of action, which can potentiate the efficacy of chemotherapy. Ursula Matulonis: Incredibly exciting. What's the future for the drug? What are your next plans? Nicoletta Colombo: Yeah, of course. One thing I didn't say is that also the toxicity profile was quite good. And, we did not observe any increase in toxicity, even though I must say all patients receive prophylactic GCSF, but also in the comparator arm, 46% receive GCSF. So drug, well tolerated. Quality of life data very good, no, no detrimental effect. And that's why we want to do a prospective randomized phase three study. And this is planned, and we'll start at the end of the year. It's called ROSELLA. And so more than 300 patients, 360 patients will be randomized to receive Relacorilant plus Nab-Paclitaxel. Theirs is a physician choice chemo could be taxane, Nab-Paclitaxel, or liposomal doxorubicin. And the primary point will be investigator assessed progression free survival. And of course also a key secondary endpoint will be overall survival. Ursula Matulonis: Yeah. Awesome. Congratulations again. Really wonderfully conducted trial and really promising results. So thank you so much. Nicoletta Colombo: Thank you. Thank you. Thank you very much.

Related Videos

Head and Neck Cancer

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).

 

Breast Cancer

Timothy J. Whelan, MD: When Can Radiotherapy Be Avoided After Breast-Conserving Surgery?

Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low rates of local tumor recurrence at 5 years. These patients, the research suggests, may be able to forgo radiotherapy (Abstract LBA501).

Lymphoma

Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab maintenance, may set a new benchmark for patients aged 65 or older with mantle cell lymphoma. With a median progression-free survival of 6.7 years, the ibrutinib combination is more beneficial than currently used chemoimmunotherapy (approximately 1.5–3.5 years) (Abstract LBA7502).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate cancer. The results corroborate the benefit of enzalutamide with improved overall survival, and involve some exploratory subgroup analyses (Abstract LBA5004).

Skin Cancer

Georgina V. Long, MD, PhD, on Melanoma: New Data on Pembrolizumab, Dabrafenib, and Trametinib

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses findings from the NeoTrio trial on neoadjuvant pembrolizumab alone, in sequence with, or concurrent with dabrafenib plus trametinib in patients with resectable BRAF-mutant stage III melanoma. The study may help clinicians determine the optimal combination of therapy (Abstract 9503).

Advertisement

Advertisement




Advertisement